ViaCyte, Inc. (formerly Novocell, Inc.), San Diego, California, USA.
Nat Biotechnol. 2011 Jul 31;29(8):750-6. doi: 10.1038/nbt.1931.
Using a flow cytometry-based screen of commercial antibodies, we have identified cell-surface markers for the separation of pancreatic cell types derived from human embryonic stem (hES) cells. We show enrichment of pancreatic endoderm cells using CD142 and of endocrine cells using CD200 and CD318. After transplantation into mice, enriched pancreatic endoderm cells give rise to all the pancreatic lineages, including functional insulin-producing cells, demonstrating that they are pancreatic progenitors. In contrast, implanted, enriched polyhormonal endocrine cells principally give rise to glucagon cells. These antibodies will aid investigations that use pancreatic cells generated from pluripotent stem cells to study diabetes and pancreas biology.
我们使用基于流式细胞术的商业抗体筛选方法，鉴定了来源于人胚胎干细胞（hES）的胰腺细胞类型的表面标记物。我们发现 CD142 可富集胰腺内胚层细胞，CD200 和 CD318 可富集内分泌细胞。经移植入小鼠后，富集的胰腺内胚层细胞可产生包括功能性胰岛素分泌细胞在内的所有胰腺谱系细胞，表明其为胰腺祖细胞。相比之下，植入的、富含多激素的内分泌细胞主要产生胰高血糖素细胞。这些抗体将有助于使用多能干细胞生成的胰腺细胞来研究糖尿病和胰腺生物学。
